WES analysis of tumor and tail samples. (A) Percentages of targeted bases covered by at least 2×, 10×, 20×, 30×, 40×, 50×, and 100× sequencing reads (top). (B) Variant allele frequencies of somatic mutations in each tumor (T-LBL from p53^−/− mice, n = 3; T-LBL from p53^−/− V-Del, n = 3; T-LBL from p53^−/− V-Fus, n = 4; Lym from p53^−/− V-Del, n = 2; and Lym from p53^−/− V-Fus, n = 5). Mutations identified in human targeted capture sequencing data^2,4  are shown in orange, and those identified in human WES data²  in blue. (C) Focal SCNAs identified through the GISTIC 2.0 algorithm using WES data. Amplified regions are shown in red; deleted regions are shown in blue. Chromosome 15qD1 includes the Myc locus. (D) High-level amplification of the Myc locus identified in Lym from 2 p53^−/−VAV1-Tg mice. (E) Immunofluorescent staining for indicated markers in thymus from, p53^−/− V-Del, and p53^−/− V-Fus mice harboring T-LBL (i), and in spleens of p53^−/− V-Del and p53^−/− V-Fus mice harboring Lym (ii). Original magnification ×400. Scale bars, 10 µm. The percentage at the bottom right corner is positivity in the tumor cells. CD3, red; Myc, green; 4′,6-diamidino-2-phenylindole (DAPI), blue. (F) Comutation plots including the spectrum of somatic mutations and focal SCNAs. (G) Rearrangements of TCR genes identified through the MiXCR algorithm using WES data. The y-axis indicates each rearranged TCR gene with a certain complementarity-determining region 3 (CDR3) sequence. Distinct CDR3 regions are indicated by alternating colors within each sample; colors are indicated in descending order and do not indicate sequence identity.